Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Efficacy and safety of novel antipsychotics: A critical review
Autore:
Balestrieri, M; Vampini, C; Bellantuono, C;
Indirizzi:
Univ Udine, Chair Psychiat, Dept PMSC, I-33100 Udine, Italy Univ Udine Udine Italy I-33100 Psychiat, Dept PMSC, I-33100 Udine, Italy Dept Mental Hlth, Verona, Italy Dept Mental Hlth Verona ItalyDept Mental Hlth, Verona, Italy Univ Verona, Clin Psychopharmacol Unit, Sect Psychiat, Dept Med & Publ Hlth, I-37100 Verona, Italy Univ Verona Verona Italy I-37100 Med & Publ Hlth, I-37100 Verona, Italy
Titolo Testata:
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
fascicolo: 7, volume: 15, anno: 2000,
pagine: 499 - 512
SICI:
0885-6222(200010)15:7<499:EASONA>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOUBLE-BLIND TRIAL; NEGATIVE SYMPTOMS; SCHIZOPHRENIC-PATIENTS; PSYCHOTIC DISORDERS; OLANZAPINE TRIAL; RECEPTOR ANTAGONIST; ACUTE EXACERBATION; TERM TREATMENT; WEIGHT-GAIN; HALOPERIDOL;
Keywords:
amisulpride; olanzapine; quetiapine; ziprasidone; zotepine; antipsychotic efficacy; side effects;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
67
Recensione:
Indirizzi per estratti:
Indirizzo: Balestrieri, M Policlin Univ Udine, Clin Psichiatr, P SM Misericordia, I-33100 Udine, Italy Policlin Univ Udine P SM Misericordia Udine Italy I-33100
Citazione:
M. Balestrieri et al., "Efficacy and safety of novel antipsychotics: A critical review", HUM PSYCHOP, 15(7), 2000, pp. 499-512

Abstract

Efficacy and safety of novel antipsychotic (AP) drugs (amisulpride, olanzapine, quetiapine; ziprasidone and zotepine) have been reviewed. Data on their antipsychotic efficacy and side effects profile have been evaluated onlyon the basis of controlled trials so far published. Overall, all these drugs have shown an antipsychotic efficacy on positive symptoms of schizophrenia similar to that of the conventional AP drugs. On negative symptoms, all novel AP drugs, except quetiapine and ziprasidone, demonstrated a better efficacy than haloperidol. Long-term efficacy of these AP drugs in the maintenance treatment of schizophrenia needs to be explored by further, better-designed, epidemiological studies. The safety profile shows that the never APdrugs are generally well-tolerated and induce significantly less acute extrapyramidal side effects in comparison with haloperidol. Some methodological flaws in the experimental design of the clinical trials analysed are discussed. Although these novel AP drugs have potential clinical advantages, a number of relevant questions still remain to be addressed, in order to establish the impact of these drugs in the overall treatment of schizophrenia. Copyright (C) 2000 John Wiley & Sons, Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 18:42:46